{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:06:03Z","timestamp":1784923563997,"version":"3.55.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.juro.2007.09.028","type":"journal-article","created":{"date-parts":[[2008,1,9]],"date-time":"2008-01-09T07:22:25Z","timestamp":1199863345000},"page":"414-423","source":"Crossref","is-referenced-by-count":42,"title":["Managing Bone Loss in Men With Locally Advanced Prostate Cancer Receiving Androgen Deprivation Therapy"],"prefix":"10.1097","volume":"179","author":[{"given":"Ron S.","family":"Israeli","sequence":"first","affiliation":[{"name":"Staten Island Urological Research, Staten Island, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Jung","sequence":"additional","affiliation":[{"name":"Syntaxx Communications, Inc., Duluth, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2007.09.028_bib1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2007.09.028_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib4","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2007.09.028_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.urology.2004.07.019","article-title":"Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression","volume":"64","author":"Higano","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.09.028_bib6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib7","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jc.87.8.3656","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2007.09.028_bib8","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2007.09.028_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen-deprivation therapy increases bone mineral density in prostate cancer patients","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen-deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.juro.2007.09.028_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/ard.59.10.765","article-title":"Background for studies on the treatment of male osteoporosis: state of the art","volume":"59","author":"Kaufman","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.juro.2007.09.028_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cncr.20766","article-title":"Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy","volume":"103","author":"Tanvetyanon","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2007.09.028_bib15","series-title":"Toremifene citrate increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer","author":"Smith","year":"2006"},{"key":"10.1016\/j.juro.2007.09.028_bib16","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2007.09.028_bib17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.028_bib18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.juro.2007.09.028_bib19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"issue":"97","key":"10.1016\/j.juro.2007.09.028_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cncr.11149","article-title":"Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma","volume":"suppl.","author":"Smith","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2007.09.028_bib21","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/01.ju.0000141515.67372.e5","article-title":"The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate","volume":"172","author":"Bae","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2146\/ajhp050045.p1","article-title":"Cancer-treatment-induced bone loss, part 1","volume":"63","author":"Michaud","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.juro.2007.09.028_bib23","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","volume":"843","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.juro.2007.09.028_bib24","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.028_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2007.09.028_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.urology.2004.03.036","article-title":"Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy","volume":"64","author":"Conde","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.09.028_bib28","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/cncr.21047","article-title":"Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy","volume":"103","author":"Agarwal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2007.09.028_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2007.03.026","article-title":"Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy","volume":"70","author":"Ryan","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.09.028_bib30","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","article-title":"Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2007.09.028_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.09.028_bib32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0302-2838(03)00379-8","article-title":"Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment","volume":"44","author":"Morote","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/PL00004177","article-title":"Do men and women fracture bones at similar bone densities?","volume":"11","author":"Selby","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.juro.2007.09.028_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","article-title":"Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study","volume":"34","author":"Schuit","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.juro.2007.09.028_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.juro.2007.09.028_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/er.23.3.279","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.juro.2007.09.028_bib37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2146\/ajhp050045.p2","article-title":"Cancer-treatment-induced bone loss, part 2","volume":"63","author":"Michaud","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.juro.2007.09.028_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00002512-200320030-00002","article-title":"Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer","volume":"20","author":"Smith","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.juro.2007.09.028_bib39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-5347(01)69080-3","article-title":"Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer","volume":"167","author":"Scherr","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.028_bib40","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1210\/jc.2002-020539","article-title":"The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer","volume":"87","author":"Taxel","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2007.09.028_bib41","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.mehy.2006.04.040","article-title":"Selective estrogen receptor modulators: a possible new treatment of osteoporosis in males","volume":"67","author":"Kastelan","year":"2006","journal-title":"Med Hypotheses"},{"issue":"suppl.","key":"10.1016\/j.juro.2007.09.028_bib42","first-page":"404","article-title":"Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer","volume":"22","author":"Steiner","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.028_bib43","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.028_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JOP.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.juro.2007.09.028_bib45","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.juro.2007.09.028_bib46","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopolous","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.juro.2007.09.028_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CGC.2006.n.004","article-title":"The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel","volume":"4","author":"Saad","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.juro.2007.09.028_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ucl.2004.01.001","article-title":"Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician","volume":"31","author":"Higano","year":"2004","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.juro.2007.09.028_bib49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534707024998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534707024998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2007.09.028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:10:59Z","timestamp":1784920259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.juro.2007.09.028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1016\/j.juro.2007.09.028"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2007.09.028","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}